# TECARTUS

NDC: 71287-220
Generic name: brexucabtagene autoleucel
Labeler / Manufacturer: Kite Pharma, Inc.
Product type: CELLULAR THERAPY
Marketing category: Biologic License Application
Dosage form: SUSPENSION
Routes: INTRAVENOUS
Marketing started: 20211001

FDA application: BLA125703

## Active ingredients

- BREXUCABTAGENE AUTOLEUCEL: 1000000 1/68mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"71287-220"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=71287-220
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a16108c2-7ca7-45af-965e-54bda4713022